A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.

ABSTRACT:

Objective

MTX is widely used to treat synovitis in PsA without supporting trial evidence. The aim of our study was to test the value of MTX in the first large randomized placebo-controlled trial (RCT) in PsA.

Methods

A 6-month double-blind RCT compared MTX (15 mg/week) with placebo in active PsA. The primary outcome was PsA response criteria (PsARC). Other outcomes included ACR20, DAS-28 and their individual components. Missing data were imputed using multiple imputation methods. Treatments were compared using logistic regression analysis (adjusted for age, sex, disease duration and, where appropriate, individual baseline scores).

Results

Four hundred and sixty-two patients were screened and 221 recruited. One hundred and nine patients received MTX and 112 received pl

SUBMITTER: Kingsley GH 

PROVIDER: S-EPMC3397466 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature